Press
Office

Here, we publish important new scientific research and materials, discuss significant NGP category developments in the media, report on scientific conferences we’ve attended, and more. Please note not all of this content is available in certain territories.

Blog Categories

Research shows blu vapour significantly reduces in-vitro toxicity – up to 99% fewer harmful chemicals

By Grant O’ Connell, Strategic Science & Policy Engagement Director New peer-reviewed, published research1 by Imperial Brands continues to consolidate its pre-clinical evidence in the ongoing vaping vs. smoking debate. myblu vape products may offer a significantly less harmful alternative for adult smokers who would otherwise continue to smoke. “In chemical terms, myblu vapour is […]

1 Jun 2020

BTH #6: Does vaping increase the risk of oral infections and inflammation?

Behind the Headlines is a regular feature taking a slightly deeper dive into a piece of recent media coverage of NGP research. This edition’s story: In late February a number of outlets, including The Telegraph, reported vapers were “more likely to have gum disease”. The Daily Mail stated vape use “alters the mouth’s microbiome and […]

20 May 2020

New Zealand: vaping, retail and public health

Ahead of new legislation for the next generation of nicotine products in New Zealand, Strategic Science & Policy Engagement Director Grant O’Connell explains Imperial Brands’ stance on selling vapes. For the past five years, New Zealand smokers have been embracing the new generation of less harmful alternatives to conventional cigarettes. The number of adult smokers […]

13 May 2020

The science underpinning our NGPs – and a world Beyond Smoke…

By Grant O’Connell, Strategic Science and Policy Engagement Director Beyond Smoke is an exciting new manifesto from Imperial Brands. It explains the scientific approach underpinning the development of our Next Generation Products (NGPs), and how our belief in the transformative potential of our NGP portfolio for adult smokers across the globe is grounded in the […]

24 Apr 2020

Product quality is vital in reassuring adult smokers about vaping

By Joe Thompson, Group Science and Regulatory Affairs Director 2019 was awash with negative media stories about vaping and lung disease, particularly in the US. Accurate, timely and complete reporting around the US EVALI developments from the media has been sadly lacking.  There now seems to be consensus from the regulatory authorities in the US and […]

20 Apr 2020

Snus and the EU – a golden public health opportunity?

By Alan Hardacre, Head of Group Corporate Affairs Many people – adult smokers and non-smokers alike – may well ask: ‘what is snus?’ Even though the oral tobacco product has been around for several centuries, it’s largely unknown, and misunderstood, outside of its native Scandinavia. The EU’s current ban on snus – with only Sweden […]

13 Mar 2020

Showing 91 to 96 of 116 posts

Subscribe via Email